TV Review: Zembla – What are the consequences of the global trade in donor sperm?
By Dr. Coco Newton,
Progress Educational Trust
| 03. 30. 2026
Have you ever wondered what it means to have dozens of half-siblings across the world – or to never know where half of your genetic identity comes from? A recent episode of Zembla explores the human consequences of the global trade in donor sperm...
Have you ever stopped to consider what it must be like to have 17 or more half-brothers and sisters? Or what it would mean if you could never find out where half of 'you' came from? A recent episode of Dutch investigative journalism programme Zembla explores exactly these questions, in an unassuming and deeply human way. Through a series of frank interviews with donor-conceived children and their parents, doctors, advocates and donors, it exposes the hidden costs of the international sperm donation industry on the lives of those most affected.
The episode opens with a technology-marvelling tour of Cryos International in Denmark, one of the world's largest sperm banks. Watching it, you feel the programme is not a dramatised depiction of isolated incidents where one man purportedly fathered 1000s of children (see BioNews 1257), but...
Related Articles
By Rob Stein, NPR | 04.23.2026
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf.
The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as...
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...